Amiodarone Explained

Watchedfields:changed
Verifiedrevid:464394155
Pronounce: or
Tradename:Cordarone, Nexterone, Pacerone, others
Dailymedid:Amiodarone
Pregnancy Au:C
Routes Of Administration:By mouth, intravenous, intraosseous
Atc Prefix:C01
Atc Suffix:BD01
Legal Au:S4
Legal Ca:Rx-only
Legal Us:Rx-only
Legal Us Comment:[1] [2] [3]
Bioavailability:20–55%
Protein Bound:96%
Metabolism:Liver
Elimination Half-Life:58 d (range 15–142 d)
Excretion:Primarily liver and bile
Cas Number:1951-25-3
Pubchem:2157
Iuphar Ligand:2566
Drugbank:DB01118
Chemspiderid:2072
Unii:N3RQ532IUT
Kegg:D02910
Chebi:2663
Chembl:633
Iupac Name:(2-ethyl)diethylamine
C:25
H:29
I:2
N:1
O:3
Smiles:CCN(CC)CCOc1c(I)cc(cc1I)C(=O)c2c3ccccc3oc2CCCC
Stdinchi:1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3
Stdinchikey:IYIKLHRQXLHMJQ-UHFFFAOYSA-N

Amiodarone is an antiarrhythmic medication used to treat and prevent a number of types of cardiac dysrhythmias. This includes ventricular tachycardia, ventricular fibrillation, and wide complex tachycardia, atrial fibrillation, and paroxysmal supraventricular tachycardia. Evidence in cardiac arrest, however, is poor.[4] It can be given by mouth, intravenously, or intraosseously. When used by mouth, it can take a few weeks for effects to begin.[5]

Common side effects include feeling tired, tremor, nausea, and constipation. As amiodarone can have serious side effects, it is mainly recommended only for significant ventricular arrhythmias. Serious side effects include lung toxicity[6] such as interstitial pneumonitis, liver problems, heart arrhythmias, vision problems, thyroid problems, and death. If taken during pregnancy or breastfeeding it can cause problems in the fetus or the infant. It is a class III antiarrhythmic medication. It works partly by increasing the time before a heart cell can contract again.[7] [5]

Amiodarone was first made in 1961 and came into medical use in 1962 for chest pain believed to be related to the heart.[8] It was pulled from the market in 1967 due to side effects. In 1974 it was found to be useful for arrhythmias and reintroduced.[9] It is on the World Health Organization's List of Essential Medicines.[10] It is available as a generic medication.[7] In 2021, it was the 235th most commonly prescribed medication in the United States, with more than 1million prescriptions.[11] [12] [5]

Medical uses

Amiodarone has been used both in the treatment of acute life-threatening arrhythmias as well as the long-term suppression of arrhythmias.[13] Amiodarone is commonly used to treat different types of abnormal heart rhythms, such as atrial arrhythmias (supraventricular arrhythmias) and ventricular arrhythmias.[13]

Atrial arrhythmias and supraventricular arrhythmias are terms often used interchangeably to refer to abnormal heart rhythms originating from the upper chambers of the heart, known as the atria. These types of arrhythmias include conditions such as atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia. They are collectively referred to as supraventricular or atrial arrhythmias because they occur above (supra) the ventricles in the electrical conduction system of the heart.[14]

Ventricular arrhythmias are abnormal heart rhythms that originate in the ventricles, which are the lower chambers of the heart. These arrhythmias can be potentially life-threatening and may disrupt the heart's ability to pump blood effectively.[14]

Amiodarone can be effective in treating conditions like ventricular fibrillation (a rapid and irregular heartbeat), ventricular tachycardia (fast heartbeat originating from the lower chambers), and cardiac arrest due to shock-resistant ventricular fibrillation.[13]

In cases where a patient is experiencing shock-resistant ventricular arrhythmias including stable ventricular tachycardia or unstable ventricular fibrillation, amiodarone may be used.[15] A recent study suggested that another antiarrhythmic, procainamide, may be more effective in stopping ventricular tachycardia – with less side effects and a higher survival rate in patients requiring multiple shocks.[16] However, due to a small sample size and lack of statistical significance, more evidence is required, and amiodarone remains the drug of choice in ventricular arrythmias.

Amiodarone is also commonly used as the first-line therapy for patients who receive shocks from implantable cardioverter defibrillators caused by ventricular arrhythmias. Combining amiodarone with beta-blockers has been shown to reduce the likelihood of experiencing appropriate shocks from implantable cardioverter defibrillators.[13]

Cardiac arrest

Defibrillation is the treatment of choice for ventricular fibrillation and pulseless ventricular tachycardia resulting in cardiac arrest. While amiodarone has been used in shock-refractory cases, evidence of benefit is poor.[4] Although amiodarone does not appear to improve survival in those who had a cardiac arrest in-hospital,[17] some studies suggested that early administration of amiodarone was associated with better survival and positive outcomes for people who had a cardiac arrest out-of-hospital.[18] [19]

Ventricular tachycardia

Amiodarone may be used in the treatment of ventricular tachycardia in certain instances.[20] Individuals with hemodynamically unstable ventricular tachycardia should not initially receive amiodarone. These individuals should be cardioverted.

Amiodarone can be used in individuals with hemodynamically stable ventricular tachycardia. In these cases, amiodarone can be used regardless of the individual's underlying heart function and the type of ventricular tachycardia; it can be used in individuals with monomorphic ventricular tachycardia, but is contraindicated in individuals with polymorphic ventricular tachycardia as it is associated with a prolonged QT interval which will be made worse with anti-arrhythmic drugs.[21]

Atrial fibrillation

Individuals who have undergone open heart surgery are at an increased risk of developing atrial fibrillation (or AF) in the first few days post-procedure.[13] [22] [23] In the ARCH trial, intravenous amiodarone (2 g administered over 2 d) has been shown to reduce the incidence of atrial fibrillation after open heart surgery when compared to placebo.[24] [25] However, clinical studies have failed to demonstrate long-term efficacy and have shown potentially fatal side effects such as pulmonary toxicities. While amiodarone is not approved for AF by the US Food and Drug Administration (FDA), it is a commonly prescribed off-label treatment due to the lack of equally effective treatment alternatives.[26] [27]

So-called 'acute onset atrial fibrillation', defined by the North American Society of Pacing and Electrophysiology (NASPE) in 2003, responds well to short-duration treatment with amiodarone.[28] This has been demonstrated in seventeen randomized controlled trials, of which five included a placebo arm. The incidence of severe side effects in this group is low.[29] [30] [31]

Amiodarone is an effective, antiarrhythmic-of-choice in achieving cardioversion to sinus rhythm in critical care populations with new onset atrial fibrillation (NOAF). However, other anti-arrhythmic agents may exert superior rhythm control, rate control and lower mortality rate which may be more favourable than amiodarone in specific cases.[32]

Contraindications

Women who are pregnant or may become pregnant are strongly advised not to take amiodarone. Since amiodarone can be expressed in breast milk, women taking the drug are advised to stop nursing.

It is contraindicated in individuals with sinus nodal bradycardia, atrioventricular block, and second or third-degree heart block who do not have an artificial pacemaker.

Individuals with baseline depressed lung function should be monitored closely if amiodarone therapy is to be initiated.

Formulations of amiodarone that contain benzyl alcohol should not be given to neonates, because the benzyl alcohol may cause the potentially fatal "gasping syndrome".[33]

Amiodarone can worsen the cardiac arrhythmia brought on by digitalis toxicity.

Contraindications of amiodarone also include:

There are no specific guidelines for endurance or high-intensity exercise while taking amiodarone. However, since amiodarone may cause bradycardia and QTc prolongation which can affect exercise capacity and increase the risk of arrhythmias during intense exercise, it would generally be advisable for patients taking this medication to consult their healthcare provider before engaging in high-intensity physical activities such as strenuous endurance exercises.[13]

Side effects

At oral doses of 400 mg per day or higher, amiodarone can have serious, varied side effects, including toxicity to the thyroid gland, liver, lung, and retinal functions, requiring clinical surveillance and regular laboratory testing.[34] Allergic reactions to amiodarone may occur.[34] Most individuals administered amiodarone on a chronic basis will experience at least one side effect. In some people, daily use of amiodarone at 100 mg oral doses can be effective for arrhythmia control with no or minimal side effects.

Some common side effects include:

Amiodarone can potentially cause renal toxicity, but solid studies on whether amiodarone may be toxic to the kidneys are lacking.[41]

Lung

Side effects of oral amiodarone at doses of 400 mg or higher include various pulmonary effects.[42] The most serious reaction is interstitial lung disease. Risk factors include high cumulative dose, more than 400 milligrams per day, duration over two months, increased age, and preexisting pulmonary disease. Some individuals were noted to develop pulmonary fibrosis after a week of treatment, while others did not develop it after years of continuous use.[42] Common practice is to avoid the agent if possible in individuals with decreased lung function.

The most specific test of pulmonary toxicity due to amiodarone is a dramatically decreased DLCO noted on pulmonary function testing.

Thyroid

Induced abnormalities in thyroid function are common.[36] [34] In approximately 15-20% of patients, amiodarone treatment results in thyroid dysfunction, either amiodarone-induced hypothyroidism or amiodarone-induced thyrotoxicosis.[43] [44] [20] Both under- and overactivity of the thyroid may occur.[34]

Amiodarone is structurally similar to thyroxine and also contains iodine. Both of these factors contribute to the effects of amiodarone on thyroid function.[20] [43] [45] [46] Amiodarone also causes an anti-thyroid action, via Plummer and Wolff–Chaikoff effects, due its large amount of iodine in its molecule, which causes a particular "cardiac hypothyroidism" with bradycardia and arrhythmia.[47] [48]

Thyroid function should be checked at least every six months.[49]

Eye

Corneal micro-deposits (cornea verticillata,[52] also called vortex or whorl keratopathy) are almost universally present (over 90%) in individuals taking amiodarone longer than 6 months, especially doses greater than 400 mg/day. These deposits typically do not cause any symptoms. About 1 in 10 individuals may complain of a bluish halo. Anterior subcapsular lens deposits are relatively common (50%) in higher doses (greater than 600 mg/day) after 6 months of treatment.Optic neuropathy, nonarteritic anterior ischemic optic neuropathy (N-AION), occurs in 1–2% of people and is not dosage dependent.[53] Bilateral optic disc swelling and mild and reversible visual field defects can also occur.

Loss of eyelashes has been linked to amiodarone use.[54]

Liver

Abnormal liver enzyme results are common in people taking amiodarone.[34] Much rarer are jaundice, hepatomegaly (liver enlargement), and hepatitis (inflammation of the liver).[55]

In clinical observations, it has been noted that the administration of amiodarone, even at lower therapeutic doses, has been associated with the development of a condition mimicking alcoholic cirrhosis. This condition, often referred to as pseudo-alcoholic cirrhosis, presents with similar histopathological features to those observed in patients with alcoholic cirrhosis.[56] [57] However, this extreme adverse event manifestation—pseudo-alcoholic cirrhosis caused by low dose amiodarone—is very rare.[58]

Skin

Long-term administration of amiodarone (usually more than eighteen months) is associated with a light-sensitive blue-grey discoloration of the skin, sometimes called ceruloderma; such patients should avoid exposure to the sun and use sunscreen that protects against ultraviolet-A and -B. The discoloration will slowly improve upon cessation of the medication, however, the skin color may not return completely.[59]

Pregnancy and breastfeeding

Use during pregnancy may result in a number of problems in the infant including thyroid problems, heart problems, neurological problems, and preterm birth.[60] Use during breastfeeding is generally not recommended though one dose may be okay.[60]

Other

Long-term use of amiodarone has been associated with peripheral neuropathies.[61]

Amiodarone is sometimes responsible for epididymitis. Amiodarone accumulates in the head of the organ and can cause unilateral or bilateral inflammation. It tends to resolve if amiodarone is stopped.[62]

Some cases of gynecomastia have been reported in men on amiodarone.[63]

A retrospective cohort study found an increased risk of digestive, liver, head and neck and liver cancers amongst male patients exposed to amiodarone versus female participants in the same study and the general population.[64] This study also identified that the Standardized Incidence Ratio of cancer occurrence increased significantly in males aged 20-59 and >80 years old who were exposed to a higher dose of Amiodarone in comparison to those exposed to a lower dose. This suggests that there is a dose-effect relationship. These results should be interpreted with caution due to limitations of the study design and care should be taken prior to altering current clinical and prescribing practices. Amiodarone and its effect on cancer is still a topic that requires more robust research.

Drug-drug interactions

The pharmacokinetics of numerous drugs, including many that are commonly administered to individuals with heart disease, are affected by amiodarone.

Amiodarone has particularly important interactions with the following drugs:

Amiodarone inhibits the action of the cytochrome P450 isozyme family; such inhibition reduces the clearance of many drugs, including the following:

In 2015, Gilead Sciences warned healthcare providers about people who began taking the hepatitis C drugs ledipasvir/sofosbuvir or sofosbuvir along with amiodarone, who developed abnormally slow heartbeats or died of cardiac arrest.[66]

Metabolism

Amiodarone is extensively metabolized in the liver by CYP3A4, a member of the cytochrome P450 superfamily of enzymes, therefore, amiodarone and can affect the metabolism of numerous other drugs that depend on cytochrome P450, such as digoxin, phenytoin, warfarin, etc.[26] [67] [68] [69]

The major metabolite of amiodarone is desethylamiodarone (DEA), which also has antiarrhythmic properties.[26]

The metabolism of amiodarone is inhibited by grapefruit juice, leading to elevated serum levels of amiodarone.

On 8 August 2008, the US Food and Drug Administration (FDA) issued a warning of the risk of rhabdomyolysis, which can lead to kidney failure or death, when simvastatin is used with amiodarone. This interaction is dose-dependent with simvastatin doses exceeding 20 mg. This drug combination, especially with higher doses of simvastatin, should be avoided.[70] Amiodarone is extensively metabolized in the liver. The primary metabolic pathway of amiodarone is by cytochrome P450 (CYP) enzymes, particularly CYP3A4 and CYP2C8.[65] [69] The metabolism of amiodaron can be characterized by two phases:

Amiodarone has an exceptionally long half-life due to a combination of several factors:[13]

Excretion

Excretion is primarily via the liver and the bile duct with almost no elimination via the kidney and it is not dialyzable. Elimination half-life average of 58 days (ranging from 25 to 100 days [Remington: The Science and Practice of Pharmacy 21st edition]) for amiodarone and 36 days for the active metabolite, desethylamiodarone (DEA). There is 10-50% transfer of amiodarone and DEA in the placenta as well as a presence in breast milk. Accumulation of amiodarone and DEA occurs in adipose tissue and highly perfused organs (i.e. liver, lungs), therefore, if an individual was taking amiodarone on a chronic basis if it is stopped it will remain in the system for weeks to months.

Whereas amiodarone is primarily eliminated from the body through hepatic metabolism and biliary excretion, a very small portion of amiodarone and its metabolites are excreted unchanged in urine or feces.[65] [69]

The liver plays a significant role in the elimination of amiodarone. After being extensively metabolized by cytochrome P450 enzymes, particularly CYP3A4 and CYP2C8, amiodarone is transported into bile via multidrug-resistant protein 2 (MRP2) transporter. Bile containing amiodarone and its metabolites is then released into the gastrointestinal tract.

Some of these compounds can be reabsorbed back into systemic circulation through enterohepatic recirculation, where they may undergo additional rounds of metabolism before eventually being excreted again into bile.

Although renal excretion contributes only minimally to the elimination of amiodarone, dose adjustment based on kidney function is generally not necessary. This is because most patients with normal renal function can adequately clear the drug through hepatic metabolism and biliary elimination pathways.[13]

Pharmacology

Amiodarone is categorized as a class III antiarrhythmic agent, and prolongs phase 3 of the cardiac action potential, the repolarization phase where there is normally decreased calcium permeability and increased potassium permeability. It has numerous other effects, however, including actions that are similar to those of antiarrhythmic classes Ia, II, and IV.

Amiodarone is a blocker of voltage gated potassium (KCNH2) and voltage gated calcium channels (CACNA2D2).[72]

Amiodarone slows the conduction rate and prolongs the refractory period of the SA and AV nodes.[73] It also prolongs the refractory periods of the ventricles, bundles of His, and the Purkinje fibers without exhibiting any effects on the conduction rate.[73] Amiodarone has been shown to prolong the myocardial cell action potential duration and refractory period and is a non-competitive β-adrenergic inhibitor.[74]

It also shows beta blocker-like and calcium channel blocker-like actions on the SA and AV nodes, increases the refractory period via sodium- and potassium-channel effects, and slows intra-cardiac conduction of the cardiac action potential, via sodium-channel effects. It is suggested that amiodarone may also exacerbate the phenotype associated with Long QT-3 syndrome causing mutations such as ∆KPQ. This effect is due to a combination of blocking the peak sodium current, but also contributing to an increased persistent sodium current.[75]

Amiodarone chemically resembles thyroxine (thyroid hormone), and its binding to the nuclear thyroid receptor might contribute to some of its pharmacologic and toxic actions.[76] The mechanisms of action of amiodarone include blocking potassium ion channels (prolonging repolarization), blocking sodium ion channels, and antagonizing alpha- and beta-adrenergic receptors.[13] The action of amiodarone can be characterized by the following effects:[13]

History

The original observation that amiodarone's progenitor molecule, khellin, had cardioactive properties, was made by the Russian physiologist Gleb von Anrep while working in Cairo in 1946.[77] Khellin is obtained from a plant extract of Khella or Ammi visnaga, a common plant in north Africa. Anrep noticed that one of his technicians had been cured of anginal symptoms after taking khellin, then used for various, non-cardiac ailments. This led to efforts by European pharmaceutical industries to isolate an active compound. Amiodarone was initially developed in 1961 at the Labaz company, Belgium, by chemists Tondeur and Binon, who were working on preparations derived from khellin. It became popular in Europe as a treatment for angina pectoris.[78] [79] [80]

As a doctoral candidate at Oxford University, Bramah Singh determined that amiodarone and sotalol had antiarrhythmic properties and belonged to a new class of antiarrhythmic agents (what would become the class III antiarrhythmic agents).[81] Today the mechanisms of action of amiodarone and sotalol have been investigated in more detail. Both drugs have been demonstrated to prolong the duration of the action potential, prolonging the refractory period, by interacting among other cellular functions with K+ channels.[80]

Based on Singh's work, the Argentinian physician Mauricio Rosenbaum began using amiodarone to treat his patients who have supraventricular and ventricular arrhythmias, with impressive results. Based on papers written by Rosenbaum developing Singh's theories, physicians in the United States began prescribing amiodarone to their patients with potentially life-threatening arrhythmias in the late 1970s.[82] [83]

The US Food and Drug Administration (FDA) was reluctant to officially approve the use of amiodarone since initial reports had shown an increased incidence of serious pulmonary side effects of the drug. In the mid-1980s, the European pharmaceutical companies began putting pressure on the FDA to approve amiodarone by threatening to cut the supply to American physicians if it was not approved. In December 1985, amiodarone was approved by the FDA for the treatment of arrhythmias.[84]

Name

Amiodarone may be an acronym for its IUPAC name (2-butyl-1-benzofuran-3-yl)-[4-[2-(diethyl'''<u>am</u>'''ino)ethoxy]-3,5-diiodophenyl]methanone,[85] where ar is a placeholder for phenyl. This is partially supported by dronedarone which is noniodinated benzofuran derivative of amiodarone, where the arylmethanone is conserved.

Dosing

Amiodarone is available in oral and intravenous formulations.

Orally, it is available under the brand names Pacerone (produced by Upsher-Smith Laboratories, Inc.) and Cordarone (produced by Wyeth-Ayerst Laboratories). It is also available under the brand name Aratac (produced by Alphapharm Pty Ltd) in Australia and New Zealand, and further in Australia under the brands Cardinorm and Rithmik as well as a number of generic brands. Also Arycor in South Africa (Produced by Winthrop Pharmaceuticals.). In South America, it is known as Atlansil and is produced by Roemmers.

In India, amiodarone is marketed (produced by Cipla Pharmaceutical) under the brand name Tachyra. It is also available in intravenous ampules and vials.

The dose of amiodarone administered is tailored to the individual and the dysrhythmia that is being treated. When administered orally, the bioavailability of amiodarone is quite variable. Absorption ranges from 22 to 95%, with better absorption when it is given with food.[26]

Notes and References

  1. Web site: Pacerone- amiodarone hydrochloride tablet . DailyMed . 8 September 2021 . 29 December 2022 . https://web.archive.org/web/20221229200210/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7 . live .
  2. Web site: Cordarone (amiodarone) tablets, for oral use Initial U.S. Approval: 1985 . DailyMed . 30 October 2018 . 8 September 2021 . 29 December 2022 . https://web.archive.org/web/20221229200207/https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=350496 . live .
  3. Web site: Nexterone- Amiodarone HCl injection, solution . DailyMed . 8 September 2021 . 29 December 2022 . https://web.archive.org/web/20221229200210/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d4d66f7-fa14-e832-e053-2a95a90a8b62 . live .
  4. Ali MU, Fitzpatrick-Lewis D, Kenny M, Raina P, Atkins DL, Soar J, Nolan J, Ristagno G, Sherifali D . Effectiveness of antiarrhythmic drugs for shockable cardiac arrest: A systematic review . Resuscitation . 132 . 63–72 . November 2018 . 30179691 . 10.1016/j.resuscitation.2018.08.025 . 52154562 . 17 December 2019 . 5 March 2020 . https://web.archive.org/web/20200305122730/http://wrap.warwick.ac.uk/113491/1/WRAP-effectiveness-antiarrhythmic-drugs-cardiac-review-Nolan-2018.pdf . live .
  5. Book: 978-1-7242-7798-5 . Review of the Medical Use of Amiodarone (Nexterone, Pacerone) . 24 July 2018 . Xavier Research Press .
  6. Feduska ET, Thoma BN, Torjman MC, Goldhammer JE . Acute Amiodarone Pulmonary Toxicity . J Cardiothorac Vasc Anesth . 35 . 5 . 1485–1494 . May 2021 . 33262034 . 10.1053/j.jvca.2020.10.060 . 227253264 .
  7. Web site: Amiodarone Hydrochloride. The American Society of Health-System Pharmacists. 22 August 2016. live. https://web.archive.org/web/20160919085754/https://www.drugs.com/monograph/amiodarone-hydrochloride.html. 19 September 2016.
  8. Book: Analytical Profiles of Drug Substances and Excipients. 1992. Academic Press. 978-0-08-086115-9. 4. en. live. https://web.archive.org/web/20170908192558/https://books.google.com/books?id=IMCH-05Z6-EC&pg=PA4. 8 September 2017.
  9. Book: Fischer J, Ganellin CR . Analogue-based Drug Discovery . 2005 . John Wiley & Sons . 978-3-527-60749-5 . 12 . en. live . https://web.archive.org/web/20170908192558/https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA12 . 8 September 2017.
  10. Book: ((World Health Organization)) . World Health Organization model list of essential medicines: 21st list 2019 . 2019 . 10665/325771 . World Health Organization . World Health Organization . Geneva . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO . free .
  11. Web site: The Top 300 of 2021 . ClinCalc . 14 January 2024 . 15 January 2024 . https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  12. Web site: Amiodarone - Drug Usage Statistics . ClinCalc . 14 January 2024 . 18 January 2024 . https://web.archive.org/web/20240118021939/https://clincalc.com/DrugStats/Drugs/Amiodarone . live .
  13. Hamilton D, Nandkeolyar S, Lan H, Desai P, Evans J, Hauschild C, Choksi D, Abudayyeh I, Contractor T, Hilliard A . Amiodarone: A Comprehensive Guide for Clinicians . Am J Cardiovasc Drugs . 20 . 6 . 549–558 . December 2020 . 32166725 . 10.1007/s40256-020-00401-5 . 212682149 .
  14. Mori S, Tretter JT, Spicer DE, Bolender DL, Anderson RH . What is the real cardiac anatomy? . Clin Anat . 32 . 3 . 288–309 . April 2019 . 30675928 . 6849845 . 10.1002/ca.23340 .
  15. Larson J, Rich L, Deshmukh A, Judge EC, Liang JJ . Pharmacologic Management for Ventricular Arrhythmias: Overview of Anti-Arrhythmic Drugs . Journal of Clinical Medicine . 11 . 11 . 3233 . June 2022 . 35683620 . 9181251 . 10.3390/jcm11113233 . free .
  16. Ortiz M, Martín A, Arribas F, Coll-Vinent B, Del Arco C, Peinado R, Almendral J . Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study . European Heart Journal . 38 . 17 . 1329–1335 . May 2017 . 27354046 . 5410924 . 10.1093/eurheartj/ehw230 .
  17. Laina A, Karlis G, Liakos A, Georgiopoulos G, Oikonomou D, Kouskouni E, Chalkias A, Xanthos T . Amiodarone and cardiac arrest: Systematic review and meta-analysis . International Journal of Cardiology . 221 . 780–788 . October 2016 . 27434349 . 10.1016/j.ijcard.2016.07.138 .
  18. Lupton JR, Neth MR, Sahni R, Jui J, Wittwer L, Newgard CD, Daya MR . Survival by time-to-administration of amiodarone, lidocaine, or placebo in shock-refractory out-of-hospital cardiac arrest . Academic Emergency Medicine . 30 . 9 . 906–917 . September 2023 . 36869657 . 10.1111/acem.14716 .
  19. Perry E, Nehme E, Stub D, Anderson D, Nehme Z . The impact of time to amiodarone administration on survival from out-of-hospital cardiac arrest . Resuscitation Plus . 14 . 100405 . June 2023 . 37303855 . 10250159 . 10.1016/j.resplu.2023.100405 .
  20. Medić F, Bakula M, Alfirević M, Bakula M, Mucić K, Marić N . Amiodarone and Thyroid Dysfunction . Acta Clin Croat . 61 . 2 . 327–341 . August 2022 . 36818930 . 9934045 . 10.20471/acc.2022.61.02.20 .
  21. Resuscitation Council (UK) Peri-arrest arrhythmias – Tachycardia algorithm Retrieved 25 January 2016
  22. Web site: UpToDate . 5 February 2024 . 5 February 2024 . https://web.archive.org/web/20240205195136/https://www.uptodate.com/contents/atrial-fibrillation-and-flutter-after-cardiac-surgery . live .
  23. Web site: Atrial fibrillation after surgery: Common and undertreated? . October 2022 . 5 February 2024 . 5 February 2024 . https://web.archive.org/web/20240205195136/https://www.health.harvard.edu/heart-health/atrial-fibrillation-after-surgery-common-and-undertreated . live .
  24. Web site: Amiodarone Reduction in Coronary Heart Trial . 5 February 2024 . 5 February 2024 . https://web.archive.org/web/20240205195137/https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2010/02/22/19/19/ARCH . live .
  25. Guarnieri T, Nolan S, Gottlieb SO, Dudek A, Lowry DR . Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: the Amiodarone Reduction in Coronary Heart (ARCH) trial . Journal of the American College of Cardiology . 34 . 2 . 343–347 . August 1999 . 10440143 . 10.1016/S0735-1097(99)00212-0 . 24714524 .
  26. Amiodarone: Guidelines for Use and Monitoring . American Family Physician . December 2003 . 68 . 11 . 2189–2197 . 14677664 . Siddoway LA . 5 February 2024 . 5 February 2024 . https://web.archive.org/web/20240205195136/https://www.aafp.org/pubs/afp/issues/2003/1201/p2189.html . live .
  27. Practice Guideline Briefs . American Family Physician . April 2005 . 71 . 7 . 1434 . Neff MJ . 5 February 2024 . 5 February 2024 . https://web.archive.org/web/20240205195136/https://www.aafp.org/pubs/afp/issues/2005/0401/p1434.html . live .
  28. Acute Management of Atrial Fibrillation: Part I. Rate and Rhythm Control . American Family Physician . 15 July 2002 . 66 . 2 . 249–257 . 12152960 . King DE, Dickerson LM, Sack JL . 5 February 2024 . 5 February 2024 . https://web.archive.org/web/20240205195136/https://www.aafp.org/pubs/afp/issues/2002/0715/p249.html . live .
  29. Managing new-onset atrial fibrillation in critically ill patients: A systematic narrative review . 32209631 . 2020 . BMJ Open . 10 . 3 . e034774 . 10.1136/bmjopen-2019-034774 . 7202704 . O'Bryan LJ, Redfern OC, Bedford J, Petrinic T, Young JD, Watkinson PJ . 5 February 2024 . 5 February 2024 . https://web.archive.org/web/20240205195136/https://bmjopen.bmj.com/content/10/3/e034774 . live .
  30. Effectiveness of Amiodarone for Conversion of Atrial Fibrillation to Sinus Rhythm . 10.1001/archinte.163.7.777 . 2003 . Archives of Internal Medicine . 163 . 7 . 777–785 . 12695268 . Letelier LM, Udol K, Ena J, Weaver B, Guyatt GH . subscription . 5 February 2024 . 5 February 2024 . https://web.archive.org/web/20240205195136/https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/215367 . live .
  31. Web site: Recommendations | Atrial fibrillation: Diagnosis and management | Guidance | NICE . 27 April 2021 . 5 February 2024 . 5 February 2024 . https://web.archive.org/web/20240205195137/https://www.nice.org.uk/guidance/ng196/chapter/Recommendations . live .
  32. Johnston BW, Chean CS, Duarte R, Hill R, Blackwood B, McAuley DF, Welters ID. Management of new onset atrial fibrillation in critically unwell adult patients: a systematic review and narrative synthesis. British Journal of Anaesthesia. 2022 May 1;128(5):759-71.
  33. Neonatal deaths associated with use of benzyl alcohol--United States . MMWR. Morbidity and Mortality Weekly Report . 31 . 22 . 290–291 . June 1982 . 6810084 . live . https://web.archive.org/web/20120830225243/http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm . 30 August 2012 . Centers for Disease Control (CDC) .
  34. Web site: Amiodarone . Drugs.com . 25 July 2022 . 18 May 2022 . 25 July 2022 . https://web.archive.org/web/20220725164122/https://www.drugs.com/amiodarone.html . live .
  35. Colunga Biancatelli RM, Congedo V, Calvosa L, Ciacciarelli M, Polidoro A, Iuliano L . Adverse reactions of Amiodarone . J Geriatr Cardiol . 16 . 7 . 552–566 . July 2019 . 31447894 . 6689516 . 10.11909/j.issn.1671-5411.2019.07.004 . 22 March 2024 .
  36. Gašparini D, Raljević D, Pehar-Pejčinović V, Klarica Gembić T, Peršić V, Turk Wensveen T . When amiodarone-induced thyroiditis meets cardiomyopathy with excessive trabeculation: a case report . . 10 . 1212965 . 2023 . 37547257 . 10401478 . 10.3389/fcvm.2023.1212965 . free .
  37. Scaramozzino MU, Sapone G, Plastina UR, Nucara M . Amiodarone-Induced Lung Toxicity: A Case Initially Not Correctly Framed . . 15 . 3 . e36818 . March 2023 . 37123694 . 10146449 . 10.7759/cureus.36818 . free .
  38. Tsai IL, Huang LT, Yu YT, Lee CT, Huang TH . Variable radiographic and histologic presentations of amiodarone-related interstitial lung disease and the importance of avoiding re-exposure . Respirol Case Rep . 11 . 6 . e01165 . June 2023 . 37249923 . 10209837 . 10.1002/rcr2.1165 .
  39. Budin CE, Cocuz IG, Sabău AH, Niculescu R, Ianosi IR, Ioan V, Cotoi OS . Pulmonary Fibrosis Related to Amiodarone-Is It a Standard Pathophysiological Pattern? A Case-Based Literature Review . . 12 . 12 . December 2022 . 3217 . 36553223 . 9777900 . 10.3390/diagnostics12123217 . free .
  40. Mitrofan CE, Cretu A, Mitrofan C, Bar C, Ghiciuc CM . Amiodarone induced lung disease . Arch Clin Cases . 9 . 3 . 126–132 . 2022 . 36176494 . 9512125 . 10.22551/2022.36.0903.10217 .
  41. Duineveld MD, Kers J, Vleming LJ . Case report of progressive renal dysfunction as a consequence of amiodarone-induced phospholipidosis . . 7 . 9 . ytad457 . September 2023 . 37743903 . 10516635 . 10.1093/ehjcr/ytad457 .
  42. Web site: Amiodarone Side Effects . Drugs.com . 25 April 2021 . 25 July 2022 . 24 February 2016 . https://web.archive.org/web/20160224012131/http://www.drugs.com/sfx/amiodarone-side-effects.html#professional . live .
  43. Tsang W, Houlden RL . Amiodarone-induced thyrotoxicosis: a review . Can J Cardiol . 25 . 7 . 421–4 . July 2009 . 19584973 . 2723027 . 10.1016/s0828-282x(09)70512-4.
  44. Cappellani D, Bartalena L, Bogazzi F . Short review: novel concepts in the approach to patients with amiodarone-induced thyrotoxicosis . J Endocrinol Invest . 47. 2. 275–283. September 2023 . 37731073 . 10.1007/s40618-023-02168-3 . 262088052 . free . 10859339 .
  45. Lombardi A, Inabnet WB, Owen R, Farenholtz KE, Tomer Y . Endoplasmic reticulum stress as a novel mechanism in amiodarone-induced destructive thyroiditis . The Journal of Clinical Endocrinology and Metabolism . 100 . 1 . E1-10 . January 2015 . 25295624 . 4283007 . 10.1210/jc.2014-2745 .
  46. Book: Hall GM, Hunter JM, Cooper MS . Core Topics in Endocrinology in Anaesthesia and Critical Care. 2010. Cambridge University Press. 978-1-139-48612-5. 170. en. live. https://web.archive.org/web/20170908192558/https://books.google.com/books?id=3xd9O-W1HE8C&pg=PA170. 8 September 2017.
  47. Venturi S . Evolutionary Significance of Iodine. Current Chemical Biology. 5 . 155–162. 2011. 1872-3136. 10.2174/187231311796765012. 3.
  48. Venturi S . Iodine, PUFAs and Iodolipids in Health and Disease: An Evolutionary Perspective. Human Evolution. 29 . 1–3. 185–205. 2014. 0393-9375.
  49. Bartalena L, Bogazzi F, Chiovato L, Hubalewska-Dydejczyk A, Links TP, Vanderpump M . 2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction . European Thyroid Journal . 7 . 2 . 55–66 . March 2018 . 29594056 . 5869486 . 10.1159/000486957 .
  50. Batcher EL, Tang XC, Singh BN, Singh SN, Reda DJ, Hershman JM . Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation . The American Journal of Medicine . 120 . 10 . 880–885 . October 2007 . 17904459 . 10.1016/j.amjmed.2007.04.022 . 27 August 2020 . 9 August 2020 . https://web.archive.org/web/20200809085816/https://zenodo.org/record/1258726 . live .
  51. Ylli D, Wartofsky L, Burman KD . Evaluation and Treatment of Amiodarone-Induced Thyroid Disorders . The Journal of Clinical Endocrinology and Metabolism . 106 . 1 . 226–236 . January 2021 . 33159436 . 10.1210/clinem/dgaa686 . 226275566 . free .
  52. Chew E, Ghosh M, McCulloch C . Amiodarone-induced cornea verticillata . Canadian Journal of Ophthalmology. Journal Canadien d'Ophtalmologie . 17 . 3 . 96–99 . June 1982 . 7116220 .
  53. Passman RS, Bennett CL, Purpura JM, Kapur R, Johnson LN, Raisch DW, West DP, Edwards BJ, Belknap SM, Liebling DB, Fisher MJ, Samaras AT, Jones LG, Tulas KM, McKoy JM . Amiodarone-associated optic neuropathy: a critical review . The American Journal of Medicine . 125 . 5 . 447–453 . May 2012 . 22385784 . 3322295 . 10.1016/j.amjmed.2011.09.020 .
  54. Book: Roy FH . Ocular differential diagnosis . 2012 . Jaypee Highlights Medical Publishers. Panama City, Panama . 978-93-5025-571-1 . 94 . 9th . live . https://web.archive.org/web/20170908192558/https://books.google.com/books?id=94WZpuXSTasC&pg=PA94. 8 September 2017.
  55. Flaharty KK, Chase SL, Yaghsezian HM, Rubin R . Hepatotoxicity associated with amiodarone therapy . Pharmacotherapy . 9 . 1 . 39–44 . 1989 . 2646621 . 10.1002/j.1875-9114.1989.tb04102.x . 37972060 .
  56. Singhal A, Ghosh P, Khan SA . Low dose amiodarone causing pseudo-alcoholic cirrhosis . Age and Ageing . 32 . 2 . 224–225 . March 2003 . 12615569 . 10.1093/ageing/32.2.224 . free .
  57. Puli SR, Fraley MA, Puli V, Kuperman AB, Alpert MA . Hepatic cirrhosis caused by low-dose oral amiodarone therapy . The American Journal of the Medical Sciences . 330 . 5 . 257–261 . November 2005 . 16284489 . 10.1097/00000441-200511000-00012 .
  58. Chokesuwattanaskul R, Shah N, Chokesuwattanaskul S, Liu Z, Thakur R . Low-dose Amiodarone Is Safe: A Systematic Review and Meta-analysis . J Innov Card Rhythm Manag . 11 . 4 . 4054–4061 . April 2020 . 32368381 . 7192149 . 10.19102/icrm.2020.110403 .
  59. Murphy RP, Canavan M . Skin Discoloration from Amiodarone . The New England Journal of Medicine . 382 . 3 . e5 . January 2020 . 31940702 . 10.1056/NEJMicm1906774 . 210333420 .
  60. Web site: Amiodarone Pregnancy and Breastfeeding Warnings . Drugs.com . 8 December 2021 . en . 15 October 2020 . https://web.archive.org/web/20201015165300/https://www.drugs.com/pregnancy/amiodarone.html . live .
  61. Fraser AG, McQueen IN, Watt AH, Stephens MR . Peripheral neuropathy during long-term high-dose amiodarone therapy . Journal of Neurology, Neurosurgery, and Psychiatry . 48 . 6 . 576–578 . June 1985 . 2989436 . 1028375 . 10.1136/jnnp.48.6.576 .
  62. Thomas A, Woodard C, Rovner ES, Wein AJ . Urologic complications of neurologic medications . The Urologic Clinics of North America . 30 . 1 . 123–131 . February 2003 . 12580564 . 10.1016/S0094-0143(02)00111-8 .
  63. http://www.ccjm.org/content/71/6/511.full.pdf
  64. Su VY, Hu YW, Chou KT, Ou SM, Lee YC, Lin EY, Chen TJ, Tzeng CH, Liu CJ . May 2013 . Amiodarone and the risk of cancer: a nationwide population-based study . Cancer . 119 . 9 . 1699–1705 . 10.1002/cncr.27881 . 23568847 . 24144312 . free.
  65. Web site: Cordarone (amiodarone HCl) tables. FDA. 2010. 22 March 2024. 3 August 2023. https://web.archive.org/web/20230803071828/http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018972s042lbl.pdf. live.
  66. West, Stephen. "Gilead Warns After Hepatitis Patient on Heart Drug Dies" . Published 21 March 2015.
  67. Web site: Amiodarone | Deranged Physiology . 22 March 2024 . 5 December 2023 . https://web.archive.org/web/20231205075036/https://derangedphysiology.com/main/cicm-primary-exam/required-reading/cardiovascular-system/Chapter%20967/amiodarone . live .
  68. 10.2165/00003088-198917020-00005 . Pharmacokinetic Drug Interactions with Amiodarone . 1989 . Clinical Pharmacokinetics . 17 . 2 . 130–140 . 2673606 . Lesko L .
  69. Book: 29489285. . 2024 . Amiodarone . Florek JB, Lucas A, Girzadas D .
  70. Web site: Information on Simvastatin/Amiodarone . . 21 September 2008. https://web.archive.org/web/20080921230357/https://www.fda.gov/Cder/drug/infopage/simvastatin_amiodarone/default.htm. 21 September 2008 . live.
  71. Shleghm MR, Mircioiu C, Voicu VA, Mircioiu I, Anuta V . Estimation of the In Vivo Release of Amiodarone From the Pharmacokinetics of Its Active Metabolite and Correlation With Its In Vitro Release . Front Pharmacol . 11 . 621667 . 2020 . 33658939 . 7917713 . 10.3389/fphar.2020.621667 . free.
  72. Web site: Amiodarone. Drugbank. 28 May 2019. 23 May 2019. https://web.archive.org/web/20190523212530/https://www.drugbank.ca/drugs/DB01118. live.
  73. Book: Harris L, Williams RR . Amiodarone: pharmacology, pharmacokinetics, toxicology, clinical effects. 1986. Médecine et sciences internationales. Paris. 978-2-86439-125-8. 12.
  74. Web site: FDA Drug Label. live. https://web.archive.org/web/20170327171522/https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=11249. 27 March 2017.
  75. Ghovanloo MR, Abdelsayed M, Ruben PC . Effects of Amiodarone and N-desethylamiodarone on Cardiac Voltage-Gated Sodium Channels . Frontiers in Pharmacology . 7 . 39 . 2016 . 26973526 . 4771766 . 10.3389/fphar.2016.00039 . free .
  76. Book: Brunton LL, Lazo JS, Parker K . Goodman & Gilman's The Pharmacological Basis of Therapeutics . 11th . McGraw-Hill . New York . 2005 . 0-07-142280-3. Goodman & Gilman's The Pharmacological Basis of Therapeutics .
  77. Anrep GV, Barsoum GS, Kenawy MR, Misrahy G . Ammi Visnaga in the Treatment of the Anginal Syndrome . British Heart Journal . 8 . 4 . 171–177 . October 1946 . 18610042 . 503580 . 10.1136/hrt.8.4.171 .
  78. Deltour G, Binon F, Tondeur R, Goldenberg C, Henaux F, Sion R, Deray E, Charlier R . [Studies in the benzofuran series. VI. Coronary-dilating activity of alkylated and aminoalkylated derivatives of 3-benzoylbenzofuran] . fr . Archives Internationales de Pharmacodynamie et de Therapie . 139 . 247–254 . September 1962 . 14026835 .
  79. Charlier R, Deltour G, Tondeur R, Binon F . [Studies in the benzofuran series. VII. Preliminary pharmacological study of 2-butyl-3-(3,5-diiodo-4-beta-N-diethylaminoethoxybenzoyl)-benzofuran] . fr . Archives Internationales de Pharmacodynamie et de Therapie . 139 . 255–264 . September 1962 . 14020244 .
  80. Book: 978-1-156-39374-1. Antiarrhythmic Agents. Books LLC.
  81. Singh BN, Vaughan Williams EM . The effect of amiodarone, a new anti-anginal drug, on cardiac muscle . British Journal of Pharmacology . 39 . 4 . 657–667 . August 1970 . 5485142 . 1702721 . 10.1111/j.1476-5381.1970.tb09891.x .
  82. Rosenbaum MB, Chiale PA, Halpern MS, Nau GJ, Przybylski J, Levi RJ, Lázzari JO, Elizari MV . Clinical efficacy of amiodarone as an antiarrhythmic agent . The American Journal of Cardiology . 38 . 7 . 934–944 . December 1976 . 793369 . 10.1016/0002-9149(76)90807-9 .
  83. Rosenbaum MB, Chiale PA, Haedo A, Lázzari JO, Elizari MV . Ten years of experience with amiodarone . American Heart Journal . 106 . 4 Pt 2 . 957–964 . October 1983 . 6613843 . 10.1016/0002-8703(83)90022-4 .
  84. Web site: Drug Approval Package: Cordarone (Amiodarone Hydrochloride) Tablets. NDA #018972. U.S. Food and Drug Administration. 6 February 2014. live. https://web.archive.org/web/20140221092003/http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/18-972_Cardarone.cfm. 21 February 2014.
  85. Web site: Compound summary for CID 2157. pubchem.ncbi.nil.nih.gov. live. https://web.archive.org/web/20160324044226/https://pubchem.ncbi.nlm.nih.gov/compound/amiodarone#section=3D-Conformer. 24 March 2016.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Amiodarone".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.